Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,384,800 | 1,045,500 | 1,708,500 | 1,467,700 | 1,087,843 |
| Marketable Securities | 1,493,100 | 1,624,200 | 1,523,900 | 1,342,200 | 1,104,309 |
| Receivables | 2,660,000 | 2,455,900 | 2,305,200 | 2,243,200 | 2,202,945 |
| Inventories | 1,344,300 | 1,317,200 | 1,208,800 | 1,151,200 | 1,039,679 |
| TOTAL | $7,109,100 | $6,651,000 | $6,928,600 | $6,447,600 | $5,719,583 |
| Non-Current Assets | |||||
| PPE Net | 2,771,400 | 2,676,600 | 2,612,800 | 2,575,800 | 2,524,446 |
| Investments And Advances | 3,112,600 | 2,884,600 | 2,339,800 | 1,755,000 | 1,873,569 |
| Other Non-Current Assets | 946,200 | 961,400 | 973,600 | 956,100 | 688,015 |
| TOTAL | $6,830,200 | $6,522,600 | $5,926,200 | $5,286,900 | $5,086,030 |
| Total Assets | $13,939,300 | $13,173,600 | $12,854,800 | $11,734,500 | $10,805,610 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 335,600 | 244,000 | 239,600 | 218,200 | 172,361 |
| Other current liabilities | 821,100 | 876,700 | 741,100 | 772,100 | 781,924 |
| TOTAL | $1,765,400 | $1,713,100 | $1,511,400 | $1,442,800 | $1,417,230 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 608,700 | 592,400 | 530,700 | 452,500 | 462,945 |
| aiOther Non-Current Liabilities | 273,000 | 267,900 | 376,300 | 361,700 | 194,033 |
| TOTAL | $1,669,500 | $1,704,600 | $1,898,700 | $1,534,400 | $1,520,083 |
| Total Liabilities | $3,434,900 | $3,417,700 | $3,410,100 | $2,977,200 | $2,937,313 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,796 | 109,832 | 109,639 | 109,277 | 108,235 |
| Common Shares | 100 | 100 | 100 | 100 | 112 |
| Retained earnings | 6,587,800 | 5,918,200 | 5,725,100 | 5,254,300 | 4,433,904 |
| Other shareholders' equity | 16,100 | 16,000 | 2,600 | -12,700 | -10,890 |
| TOTAL | $10,504,400 | $9,755,900 | $9,444,700 | $8,757,300 | $7,868,300 |
| Total Liabilities And Equity | $13,939,300 | $13,173,600 | $12,854,800 | $11,734,500 | $10,805,613 |